Group 1 - Remitly Global, Inc. (RELY) closed at $18.95, with a 3.7% gain over the past four weeks, and a mean price target of $27.11 suggests a 43.1% upside potential [1] - The average price target ranges from a low of $21.00 to a high of $32.00, with a standard deviation of $3.48, indicating variability among analysts' estimates [2] - Analysts show strong agreement on RELY's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 11.1% over the past month, with no negative revisions [12] - RELY holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement [14]

Group 1 - Shares of Syndax Pharmaceuticals (SNDX) have increased by 2.2% over the past four weeks, closing at $9.57, with a mean price target of $32.33 indicating a potential upside of 237.8% [1] - The mean estimate consists of 12 short-term price targets with a standard deviation of $10.46, where the lowest estimate of $17.00 suggests a 77.6% increase, and the highest estimate of $45.00 indicates a potential surge of 370.2% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 0.5% over the past month [11][12] Group 2 - SNDX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While consensus price targets may not be reliable indicators of actual stock gains, they can provide a directional guide for price movement [14]

Market Trends - Altcoins are experiencing a surge in social media mentions and higher price targets, following Ethereum's lead [1] - Mass retail FOMO (Fear Of Missing Out) initially focused on Bitcoin, then shifted to Ethereum, with price targets exceeding $4,000 [1] Cryptocurrency Focus - The industry is tracking assets for the next significant FOMO spike [1]

Core Viewpoint - Hillman Solutions Corp. (HLMN) has seen a 13.1% increase in share price over the past four weeks, closing at $7.77, with a potential upside of 40.8% based on Wall Street analysts' mean price target of $10.94 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $2.54, indicating variability among analysts [2] - The lowest estimate is $8.00, suggesting a 3% increase, while the highest estimate is $15.00, indicating a potential surge of 93.1% [2] - A low standard deviation signifies greater agreement among analysts regarding price movement [2][9] Analyst Optimism and Earnings Estimates - Analysts show strong agreement in revising HLMN's earnings estimates upward, which is a positive indicator for potential stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.6%, with one estimate moving higher and no negative revisions [12] Zacks Rank and Investment Potential - HLMN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] - The combination of a positive earnings outlook and a strong Zacks Rank suggests a more conclusive indication of the stock's potential upside [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of HLMN's potential gains, the direction indicated by these targets appears to be a useful guide for further research [14]

Core Viewpoint - Red Robin (RRGB) has shown an 8.1% increase in stock price over the past four weeks, with a mean price target of $9.38 indicating a potential upside of 49.1% from the current price of $6.29 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $3.94, where the lowest estimate is $3.50 (44.4% decline) and the highest is $12.00 (90.8% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about RRGB's earnings prospects, as indicated by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 14.5%, with one estimate moving higher and no negative revisions [12] - RRGB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Targets - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does provide a directional guide for price movement [14]

Core Viewpoint - Nurix Therapeutics, Inc. (NRIX) has seen a 2.3% increase in share price over the past four weeks, closing at $12.44, with analysts suggesting a potential upside of 143.4% based on a mean price target of $30.28 [1] Price Targets - The average of 18 short-term price targets ranges from a low of $16.00 to a high of $41.00, with a standard deviation of $6.49, indicating variability among estimates [2] - The lowest estimate suggests a 28.6% increase from the current price, while the highest estimate indicates a 229.6% upside [2] Analyst Consensus and Earnings Estimates - Analysts are optimistic about NRIX's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.7%, with two estimates moving higher and no negative revisions [12] Zacks Rank - NRIX currently holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Price Movement Guidance - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

Group 1 - Quanex Building Products (NX) closed at $18.93, with a 9.3% gain over the past four weeks, and a mean price target of $37 indicates a potential upside of 95.5% [1] - The mean estimate includes three short-term price targets with a standard deviation of $5.57, where the lowest estimate of $31.00 suggests a 63.8% increase, and the highest estimate of $42.00 indicates a 121.9% surge [2] - Analysts show strong agreement on NX's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for NX's current year earnings has increased by 1.8% over the last 30 days, with one estimate moving higher and no negative revisions [12] - NX holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - FB Financial (FBK) shares have shown a 1.9% increase over the past four weeks, closing at $44.46, with a potential upside of 25.1% based on Wall Street analysts' price targets [1][11]. Price Targets - The average price target for FBK is $55.6, with estimates ranging from a low of $51.00 to a high of $59.00, indicating a standard deviation of $3.78 [2]. - The lowest estimate suggests a 14.7% increase, while the highest points to a 32.7% upside [2]. Analyst Consensus and Earnings Estimates - Analysts have shown strong agreement in revising earnings estimates higher, which is a positive indicator for potential stock upside [4][11]. - The Zacks Consensus Estimate for the current year has increased by 0.8% over the past month, with one estimate rising and no negative revisions [12]. Zacks Rank - FBK holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside [13]. Price Target Reliability - While consensus price targets are often used by investors, they should be approached with skepticism due to historical inaccuracies in predicting actual stock price movements [3][10]. - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price direction, serving as a starting point for further research [9].

Group 1 - Semtech (SMTC) shares have increased by 2.2% over the past four weeks, closing at $40.23, with a mean price target of $56.33 indicating a potential upside of 40% [1] - The average of 12 short-term price targets ranges from a low of $43.00 to a high of $68.00, with a standard deviation of $8.32, suggesting a variability in analyst estimates [2] - Analysts show strong agreement on SMTC's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for SMTC's current year earnings has increased by 20.4% over the past month, with four estimates rising and three falling [12] - SMTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a directional guide for price movement [14]

Group 1 - Manchester United (MANU) closed at $17.01, with an 18% gain over the past four weeks, and a mean price target of $21.97 suggests a 29.2% upside potential [1] - The mean estimate includes three short-term price targets with a standard deviation of $4.64, indicating variability among analysts; the lowest estimate is $16.90 (0.7% decline), while the highest is $26 (52.9% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with a 48.7% increase in the Zacks Consensus Estimate for the current year, indicating potential upside for the stock [12][11] Group 2 - The Zacks Rank for MANU is 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for near-term upside [13] - While price targets are often viewed as a metric for investment decisions, they can mislead investors; analysts may set overly optimistic targets due to business incentives [7][8] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]